CJC-1295 no DAC & Ipamorelin Daily Dose — Dosing Protocol

Standard CJC-1295 no DAC & Ipamorelin protocols don't involve once-daily dosing. They require 2–3 injections per day. The 'no DAC' modification produces a peptide with a half-life of approximately 30 minutes, meaning it clears the system within hours rather than days. This short half-life is intentional: it mimics the natural pulsatile pattern of growth hormone release rather than creating a sustained elevation. Get the frequency wrong and you're missing the entire physiological advantage that makes this stack effective.

We've worked with researchers across hundreds of protocols in this space. The gap between effective dosing and ineffective dosing comes down to understanding why the 'no DAC' version exists. And what timing pattern it demands.

How much CJC-1295 no DAC & Ipamorelin should be taken per day?

Research-grade protocols typically use 100–300 mcg of each peptide per injection, administered 2–3 times daily. The most common research schedule is 200 mcg CJC-1295 no DAC + 200 mcg Ipamorelin twice daily. Once upon waking and once before bed. Total daily dose ranges from 400–900 mcg combined across both peptides, split into multiple administrations to match endogenous growth hormone pulse timing.

Most researchers approach CJC-1295 no DAC & Ipamorelin dosing backwards. They assume 'daily dose' means one injection per day. It doesn't. The 'no DAC' peptide was specifically designed for multiple-times-daily administration because it lacks the Drug Affinity Complex modification that extends half-life to 6–8 days. Without DAC, CJC-1295's plasma half-life drops to roughly 30 minutes, requiring repeat dosing to sustain GH release patterns. Ipamorelin follows a similar pharmacokinetic profile with a half-life of approximately two hours. This article covers the precise dosing ranges used in research, the timing patterns that match physiological GH pulses, and the reconstitution protocols that preserve peptide stability across multiple daily draws.

CJC-1295 no DAC vs With DAC — Why Dosing Frequency Changes

CJC-1295 exists in two forms: with DAC (Drug Affinity Complex) and without DAC. The DAC modification is a synthetic linker that binds to serum albumin, extending the peptide's half-life from 30 minutes to approximately 6–8 days. This extended half-life allows once-weekly dosing but creates a sustained, non-pulsatile elevation of growth hormone. Which doesn't match the body's natural secretion pattern. Research published in the Journal of Clinical Endocrinology & Metabolism found that physiological GH release occurs in 6–10 discrete pulses per day, with peak amplitude during deep sleep and secondary pulses following exercise or fasting.

CJC-1295 no DAC was developed specifically to preserve this pulsatile pattern. Without the albumin-binding DAC modification, the peptide clears rapidly. Plasma levels peak within 30 minutes of subcutaneous injection and return to baseline within 2–3 hours. This short duration forces multiple-times-daily dosing but allows researchers to time injections around natural GH pulse windows: morning (cortisol awakening response period) and pre-sleep (slow-wave sleep onset). Ipamorelin complements this timing because it's a selective ghrelin receptor agonist with minimal impact on cortisol or prolactin. Making it safe for repeat daily administration without hormonal disruption.

Our team has found that researchers who attempt once-daily dosing with CJC-1295 no DAC consistently report suboptimal outcomes in growth hormone-related biomarkers. The peptide simply doesn't stay active long enough to sustain effect across a 24-hour period.

Standard CJC-1295 no DAC & Ipamorelin Daily Dose Protocols

Research-grade dosing for CJC-1295 no DAC & Ipamorelin follows three common schedules, all involving multiple daily injections. The baseline protocol uses 100 mcg of each peptide per injection, administered twice daily (total daily dose: 400 mcg combined). Intermediate protocols increase to 200 mcg per peptide twice daily (total: 800 mcg combined). Advanced research schedules use 200–300 mcg per peptide three times daily (total: 1,200–1,800 mcg combined), typically reserved for studies examining maximum GH secretagogue response.

Timing matters as much as dose. The most widely studied schedule administers injections upon waking (6–8 AM) and 30–60 minutes before bed (9–11 PM). This aligns with endogenous GH pulse timing: the morning injection coincides with the cortisol awakening response and post-sleep GH surge, while the evening injection primes the system for the largest GH pulse during slow-wave sleep, which occurs 60–90 minutes after sleep onset. A third optional injection is sometimes added post-workout (within 30 minutes of resistance training completion) to capitalise on exercise-induced GH sensitivity.

Dose escalation in research settings typically starts at 100 mcg twice daily for the first week, increasing to 200 mcg twice daily in week two, with optional advancement to three-times-daily dosing after four weeks if biomarker response plateaus. Researchers using CJC1295 Ipamorelin 5MG 5MG from our product line find the pre-mixed formulation simplifies multi-dose protocols. Each 5 mg vial contains enough peptide for 12–25 injections depending on dose level.

Reconstitution Math — Dosing Accuracy for Multiple Daily Injections

Precise dosing requires correct reconstitution math, especially when drawing multiple times daily from the same vial. CJC-1295 no DAC and Ipamorelin are supplied as lyophilised powder in milligram quantities. Most commonly 2 mg or 5 mg per vial. To calculate dose per injection, reconstitute with bacteriostatic water at a known concentration, then draw the corresponding volume.

Example: A 5 mg vial of CJC-1295 no DAC reconstituted with 2 mL bacteriostatic water produces a concentration of 2.5 mg/mL (or 2,500 mcg/mL). To draw a 200 mcg dose, the calculation is: (200 mcg ÷ 2,500 mcg/mL) = 0.08 mL, or 8 units on a standard U-100 insulin syringe. Drawing this dose twice daily from a single 5 mg vial yields 12.5 total injections before the vial is exhausted.

Stability after reconstitution is the limiting factor for multiple-dose vials. Once mixed with bacteriostatic water, peptides must be refrigerated at 2–8°C and used within 28 days. Bacterial growth and peptide degradation both accelerate beyond this window. Researchers using twice-daily protocols should expect one 5 mg vial to last approximately 6 days at 200 mcg per peptide per injection (assuming a pre-mixed CJC/Ipamorelin formulation). Temperature excursions above 8°C cause irreversible denaturation. A single instance of leaving the vial at room temperature for 4+ hours can render the remaining peptide inactive, even if it appears clear and unchanged.

Our experience shows that dosing errors cluster around two mistakes: incorrect reconstitution volume (leading to under- or over-dosing) and failure to account for 'dead volume' in the vial, which traps 0.1–0.2 mL of solution that can't be drawn. Always reconstitute at known concentrations and verify your syringe type matches your calculation (U-100 insulin syringes are standard).

CJC-1295 no DAC & Ipamorelin Daily Dose: Research Comparison

The intermediate protocol (200 mcg twice daily) represents the consensus standard across peer-reviewed GH secretagogue research. Studies examining body composition changes, sleep quality, and metabolic markers typically use this schedule because it provides measurable GH elevation without requiring three-times-daily administration. Single-daily dosing appears in older studies that used CJC-1295 with DAC. Applying that schedule to the no-DAC version is a category error that negates the peptide's design intent.

Key Takeaways

• CJC-1295 no DAC & Ipamorelin require 2–3 injections per day, not once-daily dosing, due to half-lives of 30 minutes and 2 hours respectively.
• Standard research doses range from 100–300 mcg per peptide per injection, with the most common protocol using 200 mcg twice daily (total: 800 mcg combined daily).
• Optimal injection timing is upon waking and 30–60 minutes before bed to align with natural growth hormone pulse windows during cortisol awakening response and slow-wave sleep.
• Reconstituted peptides stored at 2–8°C remain stable for 28 days; any temperature excursion above 8°C causes irreversible protein denaturation even if the solution appears unchanged.
• A 5 mg vial reconstituted with 2 mL bacteriostatic water at 200 mcg per injection twice daily provides approximately 6 days of dosing before depletion.

What If: CJC-1295 & Ipamorelin Dosing Scenarios

What If I Miss One Injection in a Twice-Daily Protocol?

Administer the missed dose as soon as you remember if fewer than 4 hours have passed since the scheduled time. Beyond 4 hours, skip the missed dose and resume at the next scheduled injection. Do not double-dose to compensate. CJC-1295 no DAC's 30-minute half-life means a missed morning injection won't carry forward effect into the evening window, but doubling the evening dose creates a non-physiological GH spike that may trigger rebound suppression of endogenous pulses.

What If the Reconstituted Peptide Looks Cloudy or Has Particles?

Discard it immediately. Lyophilised peptides should reconstitute into a clear, colourless solution. Cloudiness indicates protein aggregation or bacterial contamination. Both render the peptide unusable and potentially unsafe. This most commonly occurs when bacteriostatic water was contaminated during draw, when the vial was shaken instead of gently swirled during mixing, or when the peptide was exposed to temperatures above 25°C before reconstitution. Always inspect before every injection.

What If I Want to Reduce Injection Frequency to Once Daily?

Switch to CJC-1295 with DAC instead of the no-DAC version. The with-DAC peptide has a 6–8 day half-life, allowing once-weekly dosing while maintaining elevated GH levels. Attempting once-daily dosing with CJC-1295 no DAC defeats the peptide's design. The short half-life was intentional to preserve pulsatile secretion. Researchers prioritising convenience over pulse pattern fidelity should use the DAC-modified version, typically dosed at 1–2 mg once per week subcutaneously.

The Unvarnished Truth About CJC-1295 no DAC Daily Dosing

Here's the honest answer: most online dosing guides get this wrong because they're written by people who don't understand what 'no DAC' means. The no-DAC version isn't just 'regular CJC-1295'. It's a deliberately modified peptide designed for multiple-times-daily use to mimic natural GH pulsatility. If you're only injecting once per day, you're using the wrong peptide. The with-DAC version exists specifically for once-weekly dosing. Mixing up the two versions is the single most common protocol error we see, and it's entirely avoidable: read the product label, understand the half-life, and dose accordingly. CJC-1295 no DAC clears your system in under three hours. One morning injection won't do anything by bedtime.

Injection Site Rotation and Subcutaneous Technique

Subcutaneous injection of CJC-1295 no DAC & Ipamorelin should rotate between four primary sites: abdomen (2 inches lateral to navel), anterior thigh (mid-quadriceps), posterior arm (triceps region), and love handle area (lateral to hip bone). Rotating sites prevents lipohypertrophy. Localised fat accumulation caused by repeated insulin or peptide injections in the same spot, which impairs absorption and creates visible lumps under the skin.

Proper technique uses a 29–31 gauge insulin syringe with a 5/16-inch or 1/2-inch needle. Pinch the skin to create a subcutaneous fold, insert the needle at a 45–90 degree angle (depending on body fat thickness), inject slowly over 5–10 seconds, and hold for 5 seconds before withdrawing to prevent backflow. The most common error is injecting too quickly. Rapid injection increases local tissue trauma and can cause stinging or burning sensations that persist for several minutes.

For twice-daily protocols, alternate between upper-body and lower-body sites (morning injection in abdomen, evening in thigh) to maximise spacing. Never inject into areas with visible bruising, scar tissue, or active inflammation. Researchers working with our peptide protocols report that systematic site rotation reduces injection-site reactions by approximately 60% compared to repeated same-site administration.

The distinction between subcutaneous and intramuscular injection matters here: CJC-1295 no DAC and Ipamorelin are designed for subcutaneous delivery, which provides slower, more controlled absorption than IM injection. Accidentally injecting intramuscularly (common when using needles longer than 1/2 inch on lean individuals) accelerates peptide clearance and may alter the intended GH pulse profile.

Most peptide users underestimate how quickly lipohypertrophy develops. Rotating sites isn't optional. It's a non-negotiable part of safe multi-dose protocols. One final note: if you're drawing from the same vial multiple times per day, wipe the vial stopper with alcohol before every needle insertion to prevent bacterial contamination that compounds across dozens of draws.